Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 68 references it cites were found in a registry or an index; 6 of the 14 sources its claims cite were checked for support.

Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis

Open access

Abstract

A significant clinical issue encountered after a successful acute major depressive disorder (MDD) treatment is the relapse of depressive symptoms. Although continuing maintenance therapy with antidepressants is generally recommended, there is no established protocol on whether or not it is necessary to prescribe the antidepressant used to achieve remission. In this meta-analysis, the risk of relapse and treatment failure when either continuing with the same drug used to achieved remission or switching to a placebo was assessed in several clinically significant subgroups. The pooled odds ratio (OR) (±95% confidence intervals (CI)) was calculated using a random effects model. Across 40 studies (n = 8890), the relapse rate was significantly lower in the antidepressant group than the placebo group by about 20% (OR = 0.38, CI: 0.33–0.43, p < 0.00001; 20.9% vs 39.7%). The difference in the relapse rate between the antidepressant and placebo groups was greater for tricyclics (25.3%; OR = 0.30, CI: 0.17–0.50, p < 0.00001), SSRIs (21.8%; OR = 0.33, CI: 0.28–0.38, p < 0.00001), and other newer agents (16.0%; OR = 0.44, CI: 0.36–0.54, p < 0.00001) in that order, while the effect size of acceptability was greater for SSRIs than for other antidepressants. A flexible dose schedule (OR = 0.30, CI: 0.23–0.48, p < 0.00001) had a greater effect size than a fixed dose (OR = 0.41, CI: 0.36–0.48, p < 0.00001) in comparison to placebo. Even in studies assigned after continuous treatment for more than 6 months after remission, the continued use of antidepressants had a lower relapse rate than the use of a placebo (OR = 0.40, CI: 0.29–0.55, p < 0.00001; 20.2% vs 37.2%). The difference in relapse rate was similar from a maintenance period of 6 months (OR = 0.41, CI: 0.35–0.48, p < 0.00001; 19.6% vs 37.6%) to over 1 year (OR = 0.35, CI: 0.29–0.41, p < 0.00001; 19.9% vs 39.8%). The all-cause dropout of antidepressant and placebo groups was 43% and 58%, respectively, (OR = 0.47, CI: 0.40–0.55, p < 0.00001). The tolerability rate was ~4% for both groups. The rate of relapse (OR = 0.32, CI: 0.18–0.64, p = 0.0010, 41.0% vs 66.7%) and all-cause dropout among adolescents was higher than in adults. To prevent relapse and treatment failure, maintenance therapy, and careful attention for at least 6 months after remission is recommended. SSRIs are well-balanced agents, and flexible dose adjustments are more effective for relapse prevention.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 40 double-blind RCTs (n = 8,890) found that continuing the same antidepressant after remission in major depressive disorder reduced relapse and all-cause dropout versus switching to placebo. The benefit was seen overall and across many subgroups, with no significant difference in tolerability.

Key findings

  • Across 40 studies (n = 8,890), relapse was lower with continued antidepressant treatment than placebo: 20.9% vs 39.7%, pooled OR 0.38 (95% CI 0.33–0.43; NNT = 6).
  • All-cause dropout was also lower with antidepressant continuation in 32 studies (n = 7,146): 43.3% vs 58.2%, pooled OR 0.47 (95% CI 0.40–0.55; NNT = 7).
  • Tolerability did not differ significantly in 28 studies (n = 6,897): 4.1% vs 3.9%, pooled OR 1.15 (95% CI 0.79–1.67).
  • Subgroup results reported stronger relapse-prevention effects for tricyclics (25.3% difference; OR 0.30), SSRIs (21.8%; OR 0.33), and other newer agents (16.0%; OR 0.44); flexible dosing showed a larger effect than fixed dosing (OR 0.30 vs 0.41).

Methods

  • Systematic review and meta-analysis of double-blind randomized controlled discontinuation trials (“enrichment design”) in patients with MDD who had remitted on antidepressant treatment; studies with ≥12 weeks after randomization were eligible.
  • Searches covered CENTRAL (to June 14, 2018), MEDLINE (to June 12, 2018), and EMBASE (to October 10, 2018); 40 studies met inclusion criteria.
  • Main analysis used random-effects pairwise meta-analysis comparing continued antidepressant vs placebo, with odds ratios, risk differences, NNT, plus meta-regression and subgroup analyses.

Limitations

  • The paper states that several relapse-risk factors could not be assessed because too few RCTs reported them, including number/severity/chronicity of episodes, difficult-to-treat episodes, comorbid psychiatric conditions, pre-existing medical conditions, and residual symptoms.
  • The authors note a potential favorable bias from enrichment designs because only responders to acute treatment were randomized; this is an explicit limitation in the paper.
  • The paper states that pharmacologic withdrawal effects could not be fully evaluated because relapse/dropout in the short 4–8 week period could not be assessed.
  • The text also makes evident that relapse definitions varied across studies, which the authors say made subgroup analysis difficult.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41380-020-0843-0

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA flow diagram of the literature search.
Fig. 1 PRISMA flow diagram of the literature search.CC BY · PubMed Central
Fig. 2 Meta-analysis of OR for study-defined relapse.
Fig. 2 Meta-analysis of OR for study-defined relapse.CC BY · PubMed Central
Fig. 3 Meta-analysis of OR for acceptability.
Fig. 3 Meta-analysis of OR for acceptability.CC BY · PubMed Central
Fig. 4 Meta-analysis of OR for tolerability.
Fig. 4 Meta-analysis of OR for tolerability.CC BY · PubMed Central
Fig. 5 Meta-analysis of OR for relapse rate by dosing schedule.
Fig. 5 Meta-analysis of OR for relapse rate by dosing schedule.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 6 Not checked · 66 Own results and interpretations

41 more claims

Create a free account to see all 77 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 68 references

Research works printed but not linked: 1

  1. RevMan. Review Manager (RevMan). 5.3 edn. The Nordic Cochrane Centre, The Cochrane Collaboration2014.

Cited by

See all 152

Metadata

Authors
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., & Tajika, A.
Affiliations
  • Kansai Medical University (JP)
  • University of Occupational and Environmental Health Japan (JP)
  • Tokyo Medical University (JP)
  • Tottori University (JP)
  • Shiga University of Medical Science (JP)
  • Kyoto University (JP)
  • National Center of Neurology and Psychiatry (JP)
  • Akita University (JP)
  • Kyoto University Hospital (JP)
Corresponding author
Kato, Masaki
Venue
Molecular Psychiatry
Published
2020-07-23
Volume
26
Issue
1
Pages
118-133
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3045212486
Cited by
152
References
68
Citations by year
2026: 22 · 2025: 29 · 2024: 26 · 2023: 29 · 2022: 29 · 2021: 15 · 2020: 2
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Health and Labor Science Research Grants
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, antidepressant discontinuation, maintenance therapy, relapse, remission, tricyclic antidepressants, selective serotonin reuptake inhibitors, flexible dosing, treatment acceptability, antidepressant switching, treatment failure, depression recurrence prevention, antidepressant side effects, medication adherence
MeSH terms
Antidepressive Agents, Antidepressive Agents, Tricyclic, Depression, Major Depressive Disorder, Humans, Remission Induction, Selective Serotonin Reuptake Inhibitors, Controlled Clinical Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-020-0843-0
The paper
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., & Tajika, A. (2021). Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-020-0843-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.